Skip to main content
NCBI home page
Molecular Therapy logoLink to Molecular Therapy
. 2023 Apr 24;31(7):2296. doi: 10.1016/j.ymthe.2023.04.009

Long-term safety of MRI-guided administration of AAV2-GDNF and gadoteridol in the putamen of individuals with Parkinson’s disease

Matthew T Rocco, Asad S Akhter, Debra J Ehrlich, Gretchen C Scott, Codrin Lungu, Vikas Munjal, Anthony Aquino, Russell R Lonser, Massimo S Fiandaca, Mark Hallett, John D Heiss, Krystof S Bankiewicz ∗
PMCID: PMC10362408  PMID: 37098347

Main text

(Molecular Therapy, 30, 3632–3638; December 2022)

In the originally published version of this article, volumes that were in microliters (μL) were mistakenly written as milliliters (mL). This incorrect abbreviation of units occurred during copyediting and was not present in the submitted article.

All instances of this error have been changed in the article online, and Cell Press apologizes for any confusion this may have caused.

Articles from Molecular Therapy are provided here courtesy of The American Society of Gene & Cell Therapy

RESOURCES